What question did this study set out to answer?

To evaluate the efficacy of GS24-B047, a DLL3-targeting T-cell engager with an integrated costimulatory signal, in treating small cell lung cancer.

GS24-B047: A Novel DLL3-Targeting T-Cell Engager for Small Cell Lung Cancer Treatment

View Full Paper

Ask AI

Bookmark

Authors

Preclinical evaluation reveals GS24-B047 promotes strong anti-tumor activity in SCLC, indicating significant therapeutic potential.

To evaluate the efficacy of GS24-B047, a DLL3-targeting T-cell engager with an integrated costimulatory signal, in treating small cell lung cancer.
Characterized binding activity and specificity using surface plasmon resonance and flow cytometry.
Assessed in vitro functional activity in co-culture assays with human PBMCs and DLL3-expressing SCLC cell lines.
Evaluated in vivo anti-tumor efficacy using SCLC cell-derived xenograft models.
GS24-B047 bound to DLL3 with sub-nanomolar affinity and a distinct epitope recognition.
Induced strong T cell activation and had potent cytotoxicity against DLL3-expressing SCLC lines.
Demonstrated significant tumor regression in multiple xenograft models, outperforming clinical benchmarks.

Qi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Preclinical evaluation reveals GS24-B047 promotes strong anti-tumor activity in SCLC, indicating significant therapeutic potential.

To evaluate the efficacy of GS24-B047, a DLL3-targeting T-cell engager with an integrated costimulatory signal, in treating small cell lung cancer.
Characterized binding activity and specificity using surface plasmon resonance and flow cytometry.
Assessed in vitro functional activity in co-culture assays with human PBMCs and DLL3-expressing SCLC cell lines.
Evaluated in vivo anti-tumor efficacy using SCLC cell-derived xenograft models.
GS24-B047 bound to DLL3 with sub-nanomolar affinity and a distinct epitope recognition.
Induced strong T cell activation and had potent cytotoxicity against DLL3-expressing SCLC lines.
Demonstrated significant tumor regression in multiple xenograft models, outperforming clinical benchmarks.

Qi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark